|
Dec 05, 2022
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Dec 05, 2022
|
BioCryst to Present at JMP Securities Hematology & Oncology Summit
|
|
|
Nov 28, 2022
|
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health
|
|
|
Nov 10, 2022
|
BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy
|
|
|
Nov 09, 2022
|
BioCryst to Present at Upcoming Investor Conferences
|
|
|
Nov 04, 2022
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Nov 01, 2022
|
BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones
|
|
|
Oct 24, 2022
|
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
|
|
|
Oct 18, 2022
|
BioCryst to Report Third Quarter 2022 Financial Results on November 1
|
|
|
Oct 04, 2022
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
